Business ❯ Pharmaceutical Industry ❯ Clinical Trials

Regulatory Affairs

FDA Inspections FDA Designations FDA Approval Novartis

Pluvicto Added to Standard Care Extends rPFS in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

The trial’s presentation at ESMO 2025 emphasized postponement of castration-resistant progression, with Novartis targeting year-end submissions.

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer